Literature DB >> 15936949

A role for both wild-type and expanded ataxin-7 in transcriptional regulation.

Anna-Lena Ström1, Lars Forsgren, Monica Holmberg.   

Abstract

Spinocerebellar ataxia type 7 (SCA7) is a neurodegenerative disease primarily affecting the brainstem, retina and Purkinje cells of the cerebellum. The disease is caused by a polyglutamine expansion in ataxin-7, a protein found in two complexes TFTC and STAGA, involved in transcriptional regulation. Transcriptional dysregulation has been implicated in the pathology of several polyglutamine diseases. In this paper, we analyzed the effect of both wild-type and expanded ataxin-7 on transcription driven by the co-activator CBP and the Purkinje cell expressed nuclear receptor RORalpha1. We could show that transcription mediated by both CBP and RORalpha1 was repressed by expanded ataxin-7. Interestingly, repression of transcription could also be observed with wild-type full-length ataxin-7, not only on CBP- and RORalpha1-mediated transcription, but also on basal transcription. The repression could be counteracted by inhibition of deacetylation, suggesting that ataxin-7 may act as a repressor of transcription by inhibiting the acetylation activity of TFTC and STAGA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936949     DOI: 10.1016/j.nbd.2005.04.018

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  15 in total

1.  Posttranslational modification of ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-terminal caspase-7 cleavage fragment.

Authors:  Shona Mookerjee; Theodora Papanikolaou; Stephan J Guyenet; Vanitha Sampath; Amy Lin; Cathy Vitelli; Francesco DeGiacomo; Bryce L Sopher; Sylvia F Chen; Albert R La Spada; Lisa M Ellerby
Journal:  J Neurosci       Date:  2009-12-02       Impact factor: 6.167

2.  Differential degradation of full-length and cleaved ataxin-7 fragments in a novel stable inducible SCA7 model.

Authors:  Xin Yu; Abiodun Ajayi; Narasimha Rao Boga; Anna-Lena Ström
Journal:  J Mol Neurosci       Date:  2012-02-25       Impact factor: 3.444

Review 3.  Molecular Targets and Therapeutic Strategies in Spinocerebellar Ataxia Type 7.

Authors:  Anna Niewiadomska-Cimicka; Yvon Trottier
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

4.  Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7.

Authors:  Pavitra S Ramachandran; Ryan L Boudreau; Kellie A Schaefer; Albert R La Spada; Beverly L Davidson
Journal:  Mol Ther       Date:  2014-06-16       Impact factor: 11.454

Review 5.  The ubiquitin proteasome system in neuropathology.

Authors:  Norman L Lehman
Journal:  Acta Neuropathol       Date:  2009-07-14       Impact factor: 17.088

6.  Inhibition of autophagy via p53-mediated disruption of ULK1 in a SCA7 polyglutamine disease model.

Authors:  Xin Yu; Andrés Muñoz-Alarcón; Abiodun Ajayi; Kristin E Webling; Anne Steinhof; Ülo Langel; Anna-Lena Ström
Journal:  J Mol Neurosci       Date:  2013-04-18       Impact factor: 3.444

Review 7.  Molecular pathogenesis and cellular pathology of spinocerebellar ataxia type 7 neurodegeneration.

Authors:  Gwenn A Garden; Albert R La Spada
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

8.  Allele-specific silencing of mutant Ataxin-7 in SCA7 patient-derived fibroblasts.

Authors:  Janine Scholefield; Lauren Watson; Danielle Smith; Jacquie Greenberg; Matthew J A Wood
Journal:  Eur J Hum Genet       Date:  2014-03-26       Impact factor: 4.246

9.  Expanded ataxin-7 cause toxicity by inducing ROS production from NADPH oxidase complexes in a stable inducible Spinocerebellar ataxia type 7 (SCA7) model.

Authors:  Abiodun Ajayi; Xin Yu; Staffan Lindberg; Ulo Langel; Anna-Lena Ström
Journal:  BMC Neurosci       Date:  2012-07-24       Impact factor: 3.288

Review 10.  RORalpha, a pivotal nuclear receptor for Purkinje neuron survival and differentiation: from development to ageing.

Authors:  Fatiha Boukhtouche; Mohamed Doulazmi; Florence Frederic; Isabelle Dusart; Bernard Brugg; Jean Mariani
Journal:  Cerebellum       Date:  2006       Impact factor: 3.648

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.